AstraZeneca says Fasenra misses main goal in COPD trial

Investing.comWednesday, September 17, 2025 at 7:04:18 AM
AstraZeneca has announced that its drug Fasenra did not meet its primary endpoint in a recent clinical trial aimed at treating chronic obstructive pulmonary disease (COPD). This outcome is significant as it raises concerns about the drug's effectiveness in a market where effective treatments are crucial for patient care. The failure of this trial may impact AstraZeneca's position in the competitive respiratory drug market and could lead to reevaluations of their research strategies.
— Curated by the World Pulse Now AI Editorial System

Was this article worth reading? Share it

Recommended Readings
AstraZeneca reports positive Phase III results for Saphnelo in lupus trial
PositiveFinancial Markets
AstraZeneca has announced promising Phase III results for its drug Saphnelo in treating lupus, a chronic autoimmune disease. This is significant as lupus affects millions worldwide, and effective treatments are limited. The positive trial results could lead to Saphnelo becoming a vital option for patients, potentially improving their quality of life and offering hope in a field where new therapies are desperately needed.
AstraZeneca Asthma Drug Fails COPD Study for a Second Time
NegativeFinancial Markets
AstraZeneca's asthma drug Fasenra has faced a setback, failing to achieve its objectives in a late-stage trial for chronic obstructive pulmonary disease (COPD) for the second time. This failure is significant as it hampers the company's ambitions to broaden the drug's market beyond asthma, highlighting the challenges pharmaceutical companies face in developing effective treatments for complex respiratory conditions.
Goldman Sachs raises AstraZeneca stock price target on HPP drug potential
PositiveFinancial Markets
Goldman Sachs has increased its stock price target for AstraZeneca, citing the potential of its HPP drug. This move reflects confidence in the company's future growth and innovation in the pharmaceutical sector.
Editor’s Note: This is significant as it indicates investor optimism about AstraZeneca's pipeline and the potential impact of its new drug on the market. A higher stock price target can attract more investors and boost the company's market presence.
AstraZeneca drags FTSE 100 lower ahead of key central bank decisions
NegativeFinancial Markets
AstraZeneca's performance has negatively impacted the FTSE 100 index as investors await crucial decisions from central banks. This uncertainty in the market reflects broader economic concerns.
Editor’s Note: The movement of the FTSE 100 is significant as it indicates investor confidence and economic health. With central banks poised to make important decisions, the market's reaction to AstraZeneca's influence highlights the interconnectedness of corporate performance and economic policy.
AstraZeneca falls 3% as £200m Cambridge expansion put on hold
NegativeFinancial Markets
AstraZeneca's planned £200 million expansion in Cambridge has been put on hold, leading to a 3% drop in its stock price. This decision raises concerns about the company's future growth and investment strategies.
Editor’s Note: The halt in expansion is significant as it reflects potential challenges AstraZeneca faces in its operations. Investors often react negatively to such news, which can impact the company's market position and future projects.
Latest from Financial Markets
From Loans to Jobs, Here’s How a Fed Rate Cut May Affect Your Wallet
PositiveFinancial Markets
The recent Federal Reserve rate cut is set to have a positive impact on various aspects of personal finance. Borrowers may find lower interest rates on loans, making it cheaper to finance purchases or consolidate debt. For those looking to buy or sell homes, the housing market could see increased activity as mortgage rates decline. Additionally, retirees and investors in the stock market might benefit from improved economic conditions, leading to better returns. Overall, this rate cut could stimulate economic growth and enhance financial well-being for many.
Top Bessent Aide, Daniel Katz, Expected to Be Tapped as No. 2 at I.M.F.
PositiveFinancial Markets
Daniel Katz, a key aide to Bessent, is anticipated to be appointed as the second-in-command at the International Monetary Fund (IMF). This move is significant as it reflects the IMF's commitment to strong leadership during challenging economic times, and Katz's expertise could play a crucial role in shaping global financial policies.
What the Fed’s Rate Decision Means for Loans, Credit Cards, Mortgages and More
NeutralFinancial Markets
The Federal Reserve's recent decision on interest rates has significant implications for loans, credit cards, and mortgages. By maintaining or adjusting rates, the Fed influences borrowing costs for consumers and businesses alike. This decision matters because it affects how much individuals pay for loans and credit, impacting their financial health and spending habits. Understanding these changes can help people make informed decisions about their finances.
KPMG Ignored Flaws at Regional Banks Before 2023 Crisis, Senate Report Finds
NegativeFinancial Markets
A recent Senate report reveals that KPMG overlooked significant flaws at regional banks prior to the 2023 crisis, raising serious concerns about the auditing industry's practices. Senator Richard Blumenthal emphasizes the urgent need for reform in the auditing sector to prevent future financial disasters. KPMG has dismissed the report as 'misguided,' but the findings highlight the critical role of effective auditing in maintaining financial stability.
JLR supply chain staff told to apply for universal credit, union claims
NegativeFinancial Markets
The Unite union has reported that staff at JLR are facing layoffs with reduced or zero pay due to a cyber attack that has led to a shutdown of operations. This situation is concerning as it highlights the vulnerabilities in supply chains and the impact of cyber threats on employment. The call for affected workers to apply for universal credit underscores the urgent need for support during this challenging time.
The Fed meeting brings together a Trump ally with a target of his ire.
NeutralFinancial Markets
The recent Federal Reserve meeting highlighted the complex dynamics between former President Trump and current Fed Chair Jerome Powell. As Trump has often criticized Powell's policies, this meeting serves as a significant moment for both figures, reflecting the ongoing tension between political influence and economic decision-making. Understanding these interactions is crucial as they can impact market stability and economic growth.